343 related articles for article (PubMed ID: 29445029)
21. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
[TBL] [Abstract][Full Text] [Related]
23. Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate.
Ferrari S; Pieretti F; Verri E; Tolentinis L; Cesari M; Versari M; Zolezzi C; Lamanna G; Bacci G
Anticancer Drugs; 2005 Aug; 16(7):733-8. PubMed ID: 16027521
[TBL] [Abstract][Full Text] [Related]
24. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.
Daw NC; Neel MD; Rao BN; Billups CA; Wu J; Jenkins JJ; Quintana J; Luchtman-Jones L; Villarroel M; Santana VM
Cancer; 2011 Jun; 117(12):2770-8. PubMed ID: 21656756
[TBL] [Abstract][Full Text] [Related]
25. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Gaspar N; Occean BV; Pacquement H; Bompas E; Bouvier C; Brisse HJ; Castex MP; Cheurfa N; Corradini N; Delaye J; Entz-Werlé N; Gentet JC; Italiano A; Lervat C; Marec-Berard P; Mascard E; Redini F; Saumet L; Schmitt C; Tabone MD; Verite-Goulard C; Le Deley MC; Piperno-Neumann S; Brugieres L; ; ;
Eur J Cancer; 2018 Jan; 88():57-66. PubMed ID: 29190507
[TBL] [Abstract][Full Text] [Related]
26. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial.
Meyer WH; Pratt CB; Poquette CA; Rao BN; Parham DM; Marina NM; Pappo AS; Mahmoud HH; Jenkins JJ; Harper J; Neel M; Fletcher BD
J Clin Oncol; 2001 Jan; 19(1):171-82. PubMed ID: 11134210
[TBL] [Abstract][Full Text] [Related]
27. Use of amifostine in the therapy of osteosarcoma in children and adolescents.
Petrilli AS; Oliveira DT; Ginani VC; Kechichian R; Dishtchekenian A; Filho Wde M; Tanaka C; Dias CG; Latorre Mdo R; Brunetto AL; Cardoso H; Almeida MT; de Camargo B
J Pediatr Hematol Oncol; 2002; 24(3):188-91. PubMed ID: 11990304
[TBL] [Abstract][Full Text] [Related]
28. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
Janeway KA; Grier HE
Lancet Oncol; 2010 Jul; 11(7):670-8. PubMed ID: 20347613
[TBL] [Abstract][Full Text] [Related]
29. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
Bacci G; Ferrari S; Longhi A; Picci P; Mercuri M; Alvegard TA; Saeter G; Donati D; Manfrini M; Lari S; Briccoli A; Forni C;
J Chemother; 2002 Apr; 14(2):198-206. PubMed ID: 12017378
[TBL] [Abstract][Full Text] [Related]
30. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.
Lin F; Wang Q; Yu W; Tang L; Zheng S; Sun Y; Shen Z; Yao Y; Dong Y
Asia Pac J Clin Oncol; 2011 Sep; 7(3):270-5. PubMed ID: 21884438
[TBL] [Abstract][Full Text] [Related]
31. Treatment of unresectable or metastatic osteosarcoma with cisplatin or cisplatin-doxorubicin.
Pratt CB; Champion JE; Senzer N; Green AA; Rao B; Douglass E; Meyer WE; Crom DB
Cancer; 1985 Oct; 56(8):1930-3. PubMed ID: 2992753
[TBL] [Abstract][Full Text] [Related]
32. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
33. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86).
Winkler K; Bielack S; Delling G; Salzer-Kuntschik M; Kotz R; Greenshaw C; Jürgens H; Ritter J; Kusnierz-Glaz C; Erttmann R
Cancer; 1990 Oct; 66(8):1703-10. PubMed ID: 2208024
[TBL] [Abstract][Full Text] [Related]
34. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
35. Metastatic osteosarcoma.
Daw NC; Billups CA; Rodriguez-Galindo C; McCarville MB; Rao BN; Cain AM; Jenkins JJ; Neel MD; Meyer WH
Cancer; 2006 Jan; 106(2):403-12. PubMed ID: 16353204
[TBL] [Abstract][Full Text] [Related]
36. Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.
Schwartz CL; Wexler LH; Krailo MD; Teot LA; Devidas M; Steinherz LJ; Goorin AM; Gebhardt MC; Healey JH; Sato JK; Meyers PA; Grier HE; Bernstein ML; Lipshultz SE
Pediatr Blood Cancer; 2016 Jan; 63(1):54-61. PubMed ID: 26398490
[TBL] [Abstract][Full Text] [Related]
37. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
[TBL] [Abstract][Full Text] [Related]
38. Ototoxicity in children treated for osteosarcoma.
Lewis MJ; DuBois SG; Fligor B; Li X; Goorin A; Grier HE
Pediatr Blood Cancer; 2009 Mar; 52(3):387-91. PubMed ID: 19061216
[TBL] [Abstract][Full Text] [Related]
39. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
[TBL] [Abstract][Full Text] [Related]
40. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.
Bacci G; Ferrari S; Delepine N; Bertoni F; Picci P; Mercuri M; Bacchini P; Brach del Prever A; Tienghi A; Comandone A; Campanacci M
J Clin Oncol; 1998 Feb; 16(2):658-63. PubMed ID: 9469355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
